Ing. Vojtěch Illner

Introduction: Early identification of Parkinson's disease (PD) in its prodromal stage has fundamental implications for the future development of neuroprotective therapies. However, no sufficiently accurate biomarkers of prodromal PD are currently available to facilitate early identification. The vocal assessment of patients with isolated rapid eye movement sleep behaviour disorder (iRBD) and PD appears to have intriguing potential as a diagnostic and progressive biomarker of PD and related synucleinopathies. Methods and analysis: Speech patterns in the spontaneous speech of iRBD, early PD and control participants' voice calls will be collected from data acquired via a developed smartphone application over a period of 2 years. A significant increase in several aspects of PD-related speech disorders is expected, and is anticipated to reflect the underlying neurodegeneration processes. Ethics and dissemination: The study has been approved by the Ethics Committee of the General University Hospital in Prague, Czech Republic and all the participants will provide written, informed consent prior to their inclusion in the research. The application satisfies the General Data Protection Regulation law requirements of the European Union. The study findings will be published in peer-reviewed journals and presented at international scientific conferences.

Purpose: This study aimed to evaluate the reliability of different approaches for estimating the articulation rates in connected speech of Parkinsonian patients with different stages of neurodegeneration compared to healthy controls. Method: Monologues and reading passages were obtained from 25 patients with idiopathic rapid eye movement sleep behavior disorder (iRBD), 25 de novo patients with Parkinson's disease (PD), 20 patients with multiple system atrophy (MSA), and 20 healthy controls. The recordings were subsequently evaluated using eight syllable localization algorithms, and their performances were compared to a manual transcript used as a reference. Results: The Google & Pyphen method, based on automatic speech recognition followed by hyphenation, outperformed the other approaches (automated vs. hand transcription: r > .87 for monologues and r > .91 for reading passages, p < .001) in precise feature estimates and resilience to dysarthric speech. The Praat script algorithm achieved sufficient robustness (automated vs. hand transcription: r > .65 for monologues and r > .78 for reading passages, p < .001). Compared to the control group, we detected a slow rate in patients with MSA and a tendency toward a slower rate in patients with iRBD, whereas the articulation rate was unchanged in patients with early untreated PD. Conclusions: The state-of-the-art speech recognition tool provided the most precise articulation rate estimates. If speech recognizer is not accessible, the freely available Praat script based on simple intensity thresholding might still provide robust properties even in severe dysarthria. Automated articulation rate assessment may serve as a natural, inexpensive biomarker for monitoring disease severity and a differential diagnosis of Parkinsonism

Measuring the fundamental frequency of the vocal folds F-0 is recognized as an important parameter in the assessment of speech impairments in Parkinson's disease (PD). Although a number of F-0 trackers currently exist, their performance in smartphone-based evaluation and robustness against background noise have never been tested. Monologues from 30 newly-diagnosed, untreated PD patients and 30 matched healthy control participants were collected. Additive non-stationary urban and household noise at different SNR levels was added to the recordings, which were subsequently assessed by 10 freely-available and widely-used pitch-tracking algorithms. According to the comparison of all investigated pitch detectors, sawtooth inspired pitch estimator (SWIPE) was the most robust and accurate method in estimating mean F-0 and its standard deviation. However, at a low 6 dB SNR level, a combination of more algorithms may be needed to achieve the desired precision. Monopitch, calculated as F-0 standard deviation and estimated by SWIPE, proved to be robust in distinguishing between the PD and healthy control groups (p < 0.001). We anticipate that monopitch may serve as a quick and inexpensive biomarker of disease progression based on longitudinal data collected via smartphone, without any logistical or time constraints for patients and physicians. (C) 2020 Elsevier Ltd. All rights reserved.